[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.255.49. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 206
Citations 0
Comment & Response
February 2017

Risk and Benefit Information and Use of Aspirin—Reply

Author Affiliations
  • 1Division of Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
  • 2Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
  • 3Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
JAMA Intern Med. 2017;177(2):291-292. doi:10.1001/jamainternmed.2016.7991

In Reply We agree with Sperl-Hillen and colleagues that inappropriate use of aspirin for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) is common in clinical practice. This underscores the important need for improving evidence–based decision making through tools that facilitate the personalized benefit to risk assessment. The Aspirin-Guide decision support tool (freely available as an app for mobile devices and also on the web at http://www.aspiringuide.com) is designed to help busy clinicians in shared decision–making discussions with their patients regarding aspirin use.1,2 This user-friendly decision support tool rapidly provides individualized bleeding and ASCVD risk score assessments, along with an evidence-based specific recommendation for the patient based on these dual risk assessments.

×